XDC Academy

As a cutting-edge bioconjugate format designed to overcome tumor drug resistance, dpADC is plagued with complex multi-step synthesis, challenging impurity removal, and formulation precipitation issues during manufacturing.
 
This case highlights WuXi XDC’s tailored process troubleshooting for dual-site dpADC. Supported by our Process & Purification Toolbox, we achieved >70% yield via one-column purification to strip free payloads and fixed precipitation issues via buffer screening.
 
Backed by robust end-to-end conjugation expertise, WuXi XDC’s full-range technical arsenal empowers flexible dpADC development across multiple design routes, from customizable dual-site conjugation leveraging WuXiDARx™ to realize versatile DAR combinations, to branched-linker constructs with adjustable payload stoichiometry.
 
Our innovative WuXiDARx™ technology further strengthens our platform competitiveness by generating 4+2, 4+4 and 6+2 dpADC exclusively on native interchain cysteines without any antibody engineering or enzymatic modification, streamlining downstream CMC and optimizing cost efficiency.